Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;70(3):465-478.
doi: 10.1007/s12020-020-02473-4. Epub 2020 Sep 7.

Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy

Affiliations
Review

Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy

Kyung Ae Lee et al. Endocrine. 2020 Dec.

Abstract

In this review, we consider the diverse risk factors in diabetes patients beyond hyperglycemia that are being recognized as contributors to diabetic peripheral neuropathy (DPN). Interest in such alternative mechanisms has been encouraged by the recognition that neuropathy occurs in subjects with metabolic syndrome and pre-diabetes and by the reporting of several large clinical studies that failed to show reduced prevalence of neuropathy after intensive glucose control in patients with type 2 diabetes. Animal models of obesity, dyslipidemia, hypertension, and other disorders common to both pre-diabetes and diabetes have been used to highlight a number of plausible pathogenic mechanisms that may either damage the nerve independent of hyperglycemia or augment the toxic potential of hyperglycemia. While pathogenic mechanisms stemming from hyperglycemia are likely to be significant contributors to DPN, future therapeutic strategies will require a more nuanced approach that considers a range of concurrent insults derived from the complex pathophysiology of diabetes beyond direct hyperglycemia.

Keywords: Diabetes; Diabetic peripheral neuropathy; Dyslipidemia; Hypertension; Pathogenesis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. K.A. Head, Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 11(4), 294–329 (2006) - PubMed
    1. J.B. Buse, D.J. Wexler, A. Tsapas, P. Rossing, G. Mingrone, C. Mathieu, D.A. D’Alessio, M.J. Davies, 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes. Care. 43(2), 487–493 (2020). https://doi.org/10.2337/dci19-0066 - DOI - PubMed
    1. M.K. Kim, S.H. Ko, B.Y. Kim, E.S. Kang, J. Noh, S.K. Kim, S.O. Park, K.Y. Hur, S. Chon, M.K. Moon, N.H. Kim, S.Y. Kim, S.Y. Rhee, K.W. Lee, J.H. Kim, E.J. Rhee, S. Chun, S.H. Yu, D.J. Kim, H.S. Kwon, K.S. Park; Committee of Clinical Practice Guidelines, K.D.A., 2019 clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 43(4), 398–406 (2019). https://doi.org/10.4093/dmj.2019.0137 - DOI - PubMed - PMC
    1. C. Diabetes; Complications Trial Research, G., D.M. Nathan, S. Genuth, J. Lachin, P. Cleary, O. Crofford, M. Davis, L. Rand, C. Siebert, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977–986 (1993). https://doi.org/10.1056/NEJM199309303291401 - DOI
    1. D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, T.J. Orchard, P. Raskin, B. Zinman, C. Diabetes, Complications Trial/Epidemiology of Diabetes, I., Complications Study Research, G.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353(25), 2643–2653 (2005). https://doi.org/10.1056/NEJMoa052187 - DOI - PubMed

LinkOut - more resources